Drug treatment of Alzheimer's disease patients leads to expression changes in peripheral blood cells

Alzheimer's and Dementia

Volumn 6, Issue 5, 2010, Pages 386-393

  Calciano, Margaret A ^a   Zhou, Weiyin ^a   Snyder, Peter J ^b   Einstein, Richard ^a  

^a ExonHit Therapeutics Inc   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Cholinesterase inhibitors; Donepezil; Expression profiling; Galantamine; Genome wide SpliceArray; Microarray; Peripheral blood; Pharmacogenomics; Rivastigmine

Indexed keywords

BIOLOGICAL MARKER; DONEPEZIL; GALANTAMINE; RIVASTIGMINE; RNA;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD CELL; BLOOD SAMPLING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE PROBE; GENOME ANALYSIS; HUMAN; MALE; MICROARRAY ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; RNA ISOLATION; TREATMENT RESPONSE;

ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; BLOOD CELLS; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS AS TOPIC; GALANTAMINE; GENE EXPRESSION REGULATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INDANS; MICROARRAY ANALYSIS; PHENYLCARBAMATES; PIPERIDINES; PRINCIPAL COMPONENT ANALYSIS; RNA;

EID: 77949335693     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2009.12.004     Document Type: Article

References (41)

1. D.M. Mann, and P.O. Yates Neurotransmitter deficits in Alzheimer's disease and in other dementing disorders Hum Neurobiol 5 1986 147 158
2. B. Davies, D. Andrewes, R. Stargatt, D. Ames, V. Tuckwell, and S. Davis Tacrine in Alzheimer's disease Lancet 2 1989 163 164
3. C.W. Ritchie, D. Ames, T. Clayton, and R. Lai Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease Am J Geriatr Psychiatry 12 2004 358 369
4. J. Birks Cholinesterase inhibitors for Alzheimer's disease Cochrane Database Syst Rev 1 2006 CD005593
5. R.A. Hansen, G. Gartlehner, A.P. Webb, L.C. Morgan, C.G. Moore, and D.E. Jonas Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis Clin Interv Aging 3 2008 211 225
6. M.M. Husain, K. Trevino, H. Siddique, and S.M. McClintock Present and prospective clinical therapeutic regimens for Alzheimer's disease Neuropsychiatr Dis Treat 4 2008 765 777
7. R.C. Petersen, R.G. Thomas, M. Grundman, D. Bennett, R. Doody, and S. Ferris Vitamin E and donepezil for the treatment of mild cognitive impairment N Engl J Med 352 2005 2379 2388
8. M. Gupta, H. Kaur, S. Grover, and R. Kukreti Pharmacogenomics and treatment for dementia induced by Alzheimer's disease Pharmacogenomics 9 2008 895 903
9. S. Ferris, A. Nordberg, H. Soininen, T. Darreh-Shori, and R. Lane Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment Pharmacogenet Genomics 19 2009 635 646
10. R. Lane, H.H. Feldman, J. Meyer, Y. He, S.H. Ferris, and A. Nordberg Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase k-variant on progression from mild cognitive impairment to Alzheimer's disease Pharmacogenet Genomics 18 2008 289 298
11. R. Cacabelos Donepezil in Alzheimer's disease: from conventional trials to pharmacogenetics Neuropsychiatr Dis Treat 3 2007 303 333
12. A. Pilotto, M. Franceschi, G. D'Onofrio, A. Bizzarro, F. Mangialasche, and L. Cascavilla Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease Neurology 73 2009 761 767
13. C. Reitz, and R. Mayeux Endophenotypes in normal brain morphology and Alzheimer's disease: a review Neuroscience 164 2009 174 190
14. W. Zhou, M. Calciano, H. Jordan, M. Brenner, S. Johnson, and D. Wu High resolution analysis of the human transcriptome: detection of extensive alternative splicing independent of transcriptional activity BMC Genet 10 2009 63
15. M.P. Pando, V. Kotraiah, K. McGowan, L. Bracco, and R. Einstein Alternative isoform discrimination by the next generation of expression profiling microarrays Expert Opin Ther Targets 10 2006 613 625
16. P. Fehlbaum, C. Guihal, L. Bracco, and O. Cochet A microarray configuration to quantify expression levels and relative abundance of splice variants Nucleic Acids Res 33 2005 e47
17. E.L. Heinzen, W. Yoon, M.E. Weale, A. Sen, N.W. Wood, and J.R. Burke Alternative ion channel splicing in mesial temporal lobe epilepsy and Alzheimer's disease Genome Biol 8 2007 R32
18. R. Einstein, H. Jordan, W. Zhou, M. Brenner, E.G. Moses, and S.B. Liggett Alternative splicing of the g protein-coupled receptor superfamily in human airway smooth muscle diversifies the complement of receptors Proc Natl Acad Sci USA 105 2008 5230 5235
19. S.V. Kozyrev, A. Abelson, J. Wojcik, A. Zaghlool, M.V. Linga Reddy, and E. Sanchez Functional variants in the b-cell gene BANK1 are associated with systemic lupus erythematosus Nat Genet 40 2008 211 216
20. H.R. Christofk, M.G. Vander Heiden, M.H. Harris, A. Ramanathan, R.E. Gerszten, and R. Wei The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth Nature 452 2008 230 233
21. S. Boue, I. Letunic, and P. Bork Alternative splicing and evolution Bioessays 25 2003 1031 1034
22. J.A. Calarco, Y. Xing, M. Cáceres, J.P. Calarco, X. Xiao, and Q. Pan Global analysis of alternative splicing differences between humans and chimpanzees Genes Dev 21 2007 2963 2975
23. P.D. Thomas, M.J. Campbell, A. Kejariwal, H. Mi, B. Karlak, and R. Daverman Panther: a library of protein families and subfamilies indexed by function Genome Res 13 2003 2129 2141
24. P.D. Thomas, A. Kejariwal, N. Guo, H. Mi, M.J. Campbell, and A. Muruganujan Applications for protein sequence-function evolution data: mRNA/protein expression analysis and coding SNP scoring tools Nucleic Acids Res 34 web server issue 2006 W645 W650
25. D.G. Wilkinson, P.T. Francis, E. Schwam, and J. Payne-Parrish Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy Drugs Aging 21 2004 453 478
26. D.G. Wilkinson, A.P. Passmore, R. Bullock, S.W. Hopker, R. Smith, and F.C. Potocnik A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease Int J Clin Pract 56 2002 441 446
27. C.F. Bartels, F.S. Jensen, O. Lockridge, A.F. van der Spek, H.M. Rubinstein, and T. Lubrano DNA mutation associated with the human butyrylcholinesterase k-variant and its linkage to the atypical variant mutation and other polymorphic sites Am J Hum Genet 50 1992 1086 1103
28. C. Holmes, C. Ballard, D. Lehmann, A. David Smith, H. Beaumont, and I.N. Day Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase k gene variation J Neurol Neurosurg Psychiatry 76 2005 640 643
29. R. Blesa, R. Bullock, Y. He, H. Bergman, G. Gambina, and J. Meyer Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease Pharmacogenet Genomics 16 2006 771 774
30. B. Giunta, F. Fernandez, W.V. Nikolic, D. Obregon, E. Rrapo, and T. Town Inflammaging as a prodrome to Alzheimer's disease J Neuroinflammation 5 2008 51
31. M. Reale, C. Iarlori, F. Gambi, C. Feliciani, A. Salone, and L. Toma Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines J Neuroimmunol 148 2004 162 171
32. M. Noh, S. Koh, Y. Kim, H.Y. Kim, G.W. Cho, and S.H. Kim Neuroprotective effects of donepezil through inhibition of GSK-3 activity in amyloid-beta-induced neuronal cell death J Neurochem 108 2009 1116 1125
33. Y. Takada, A. Yonezawa, T. Kume, H. Katsuki, S. Kaneko, and H. Sugimoto Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons J Pharmacol Exp Ther 306 2003 772 777
34. M. Kimura, H. Komatsu, H. Ogura, and K. Sawada Comparison of donepezil and memantine for protective effect against amyloid-beta(1-42) toxicity in rat septal neurons Neurosci Lett 391 2005 17 21
35. S. Akasofu, M. Kimura, T. Kosasa, K. Sawada, and H. Ogura Study of neuroprotection of donepezil, a therapy for Alzheimer's disease Chem Biol Interact 175 2008 222 226
36. E. Arias, S. Gallego-Sandín, M. Villarroya, A.G. García, and M.G. López Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors J Pharmacol Exp Ther 315 2005 1346 1353
37. X. Zhou, A.R. Patel, F. Perez, and D.A. Jurivich Acetylcholinesterase inhibitor rivastigmine enhances cellular defenses in neuronal and macrophage-like cell lines Transl Res 153 2009 132 141
38. S. Ray, M. Britschgi, C. Herbert, Y. Takeda-Uchimura, A. Boxer, and K. Blennow Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins Nat Med 13 2007 1359 1362
39. L.D. Miller, and E.T. Liu Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine Breast Cancer Res 9 2007 206
40. J.J. Kruse, and F.A. Stewart Gene expression arrays as a tool to unravel mechanisms of normal tissue radiation injury and prediction of response World J Gastroenterol 13 2007 2669 2674
41. C.R. Acharya, D.S. Hsu, C.K. Anders, A. Anguiano, K.H. Salter, and K.S. Walters Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer JAMA 299 2008 1574 1587